Application of Dermatology Life Quality Index‐Relevant (DLQI‐R) in patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab

Application of Dermatology Life Quality Index‐Relevant (DLQI‐R) in patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab

Abstract Background Tildrakizumab is an interleukin‐23p19 inhibitor approved for the treatment of moderate‐to‐severe plaque psoriasis. The new Dermatology Life Quality Index (DLQI)‐Relevant (DLQI‐R) scoring system avoids the bias in the not relevant response option of the DLQI by adjusting the total...

Full description

Bibliographic Details
Main Authors:	Philip Laws, Kristian Gaarn Du Jardin
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Series:	JEADV Clinical Practice
Subjects:	DLQI DLQI‐R health‐related quality of life psoriasis tildrakizumab
Online Access:	https://doi.org/10.1002/jvc2.175

Similar Items

Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population
by: Diana Norris, et al.
Published: (2017-11-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023-03-01)

Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
by: J. M. Norlin, et al.
Published: (2017-08-01)

Quality of life in patients with scabies: A cross‐sectional study using Dermatology Life Quality Index (DLQI) questionnaire
by: Sushil Paudel, et al.
Published: (2023-06-01)

Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review
by: de Ruiter CC, et al.
Published: (2022-05-01)

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Boni Elewski, et al.
Published: (2020-11-01)

Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment
by: Ali Al Raddadi, et al.
Published: (2016-01-01)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021-05-01)

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
by: Sascha Gerdes, et al.
Published: (2020-07-01)

Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Steven R. Feldman, et al.
Published: (2022-04-01)

Tildrakizumab in the treatment of psoriasis – literature review
by: Katarzyna Banaszczyk
Published: (2019-08-01)

Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
by: Julia-Tatjana Maul, et al.
Published: (2024-03-01)

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
by: Andrea Chiricozzi, et al.
Published: (2020-07-01)

The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis
by: Jenny M. Norlin, et al.
Published: (2023-11-01)

Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
by: Nicoletta Bernardini, et al.
Published: (2022-10-01)

Dermatology Life Quality Index (DLQI) Score in Acne Vulgaris after Epigallocatechin-3-Gallate (EGCG) 3% as an Adjuvant of Tretinoin 0,025% Cream
by: Farah Meriana Fajrin, et al.
Published: (2023-11-01)

A quality of life study in patients with leprosy using DLQI and WHOQOL-BREF questionnaires
by: Dakshata A Tare, et al.
Published: (2021-01-01)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018-08-01)

Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest
by: Alexander Egeberg, et al.
Published: (2023-12-01)

The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
by: Georgios Kokolakis, et al.
Published: (2021-10-01)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
by: Thomas Damsin
Published: (2023-06-01)

Study on the impact of depression on the quality of life of patients with psoriasis
by: Roxana-Cristina OLTENACU, et al.
Published: (2024-02-01)

Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
by: Xiaoying Jia, et al.
Published: (2022-02-01)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
by: Näslund-Koch C, et al.
Published: (2020-09-01)

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients
by: Teodora-Larisa Timis, et al.
Published: (2023-05-01)

Quality of life in vitiligo patients: a report from Razi referral University Hospital in Tehran
by: Feizy V, et al.
Published: (2007-08-01)

Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy
by: Lyubomir A. Dourmishev, et al.
Published: (2020-03-01)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
by: Philip Mease, et al.
Published: (2020-11-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
by: Boni E. Elewski, et al.
Published: (2017-08-01)

Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis
by: Dario Buononato, et al.
Published: (2022-05-01)

Impact of multiple extragenital warts on quality of life in immune-competent Egyptian adults: a comparative cross-sectional study
by: Salah E
Published: (2018-06-01)

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
by: Marco Galluzzo, et al.
Published: (2022-05-01)

Impact on quality of life in vitiligo patients treated with narrowband ultraviolet B phototherapy
by: Yatendra S Chahar, et al.
Published: (2018-01-01)

Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)
by: Alessia Villani, et al.
Published: (2019-09-01)

A quality of life study of patients with leprosy attending the dermatology OPD of a tertiary care center of Eastern India
by: Nirmalya K Das, et al.
Published: (2020-01-01)

Dermatology Specific Quality of Life in Vitiligo Patients and Its Relation with Various Variables: A Hospital Based Cross-sectional Study
by: Nitin Mishra, et al.
Published: (2014-06-01)

Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis
by: Ahmad Jalili, et al.
Published: (2024-02-01)

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
by: Tiago Torres, et al.
Published: (2024-03-01)